Recent approaches to intracellular delivery of drugs and DNA and organelle targeting.

Intracellular delivery of various drugs, including DNA, and drug carriers can sharply increase the efficiency of various treatment protocols. However, the receptor-mediated endocytosis of drugs, drug carriers, and DNA results in their lysosomal delivery and significant degradation. The problem can be solved and therapy efficacy still further increased if the approaches for direct intracytoplasmic delivery that bypass the endocytic pathway are developed. This is especially important for many anticancer drugs (proapoptotic drugs whose primary action site is the mitochondrial membrane) and gene therapy (nuclear or mitochondrial genomes should be targeted). This review considers several current approaches for intracellular drug delivery: the use of pH-sensitive liposomes, the use of cell-penetrating proteins and peptides, and the use of immunoliposomes targeting intracellular antigens. Among intracellular targets, nuclei (gene therapy), mitochondria (proapoptotic cancer therapy and targeting of the mitochondrial genome), and lysosomes (lysosomal targeting of enzymes for the therapy of the lysosomal storage diseases) are considered. Examples of successful intracellular and organelle-specific delivery of biologically active molecules, including DNA, are presented; unanswered questions, challenges, and future trends are also discussed.

[1]  A. Prochiantz,et al.  Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent* , 1996, The Journal of Biological Chemistry.

[2]  V. Torchilin,et al.  Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. , 1996, Biochimica et biophysica acta.

[3]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Y. Tseng,et al.  Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. , 2002, Molecular pharmacology.

[5]  S. Magdassi,et al.  Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[6]  N. D. Mar,et al.  Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes , 1995, Neuroscience Letters.

[7]  P. Stern,et al.  Herpes simplex virus VP22–human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death , 2004, Biotechnology and applied biochemistry.

[8]  R Weissleder,et al.  Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. , 2001, Journal of immunological methods.

[9]  T. Bártfai,et al.  Cargo delivery kinetics of cell-penetrating peptides. , 2001, Biochimica et biophysica acta.

[10]  V. Torchilin,et al.  TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Ralph Weissleder,et al.  Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. , 2002, Bioconjugate chemistry.

[12]  B. E. Ryman,et al.  α-Mannosidase in Zinc-Deficient Rats: Possibility of Liposomal Therapy in Mannosidosis , 1974 .

[13]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[14]  F. Sharp,et al.  In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis , 2002, The Journal of Neuroscience.

[15]  Ralph Weissleder,et al.  Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells , 2000, Nature Biotechnology.

[16]  M. Murphy,et al.  Slip and leak in mitochondrial oxidative phosphorylation. , 1989, Biochimica et biophysica acta.

[17]  R. Schwendener,et al.  Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes , 1986, International journal of cancer.

[18]  B. Hoflack,et al.  Targeting of lysosomal proteins. , 2000, Seminars in cell & developmental biology.

[19]  J. Lloyd Lysosome membrane permeability: implications for drug delivery. , 2000, Advanced drug delivery reviews.

[20]  V. Torchilin,et al.  Plug and seal: Prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes , 1995, Nature Medicine.

[21]  J. E. Lee,et al.  TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells , 2002, Neurochemistry International.

[22]  S. Schwarze,et al.  In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. , 2000, Trends in pharmacological sciences.

[23]  John Calvin Reed Dysregulation of apoptosis in cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Huang,et al.  pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. , 1986, Cancer research.

[25]  A. Hoffman,et al.  Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH , 1995, Nature.

[26]  D. Wallace Mitochondrial diseases in man and mouse. , 1999, Science.

[27]  F. Szoka,et al.  Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.

[28]  S. Futaki,et al.  Arginine-rich Peptides , 2001, The Journal of Biological Chemistry.

[29]  M. Kisel,et al.  Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. , 2001, International journal of pharmaceutics.

[30]  M. Hashida,et al.  Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  M. Giacca,et al.  Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat , 2003, Cancer Gene Therapy.

[32]  T. Park,et al.  Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. , 2003, Bioconjugate chemistry.

[33]  H. Farhood,et al.  The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. , 1995, Biochimica et biophysica acta.

[34]  D. Lauffenburger,et al.  Receptor‐mediated targeting of gene delivery vectors: Insights from molecular mechanisms for improved vehicle design , 2000, Biotechnology and bioengineering.

[35]  M. Yessine,et al.  Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. , 2004, Advanced drug delivery reviews.

[36]  B. Wiesner,et al.  Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. , 1998, Biochimica et biophysica acta.

[37]  D. Crommelin,et al.  Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA , 1995, Thrombosis and Haemostasis.

[38]  Soo‐Young Choi,et al.  Transduction of Cu,Zn‐superoxide dismutase mediated by an HIV‐1 Tat protein basic domain into mammalian cells , 2000, FEBS letters.

[39]  J. Helms,et al.  Lipids as Targeting Signals: Lipid Rafts and Intracellular Trafficking , 2004, Traffic.

[40]  R. Kumar,et al.  Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. , 1994, The Journal of biological chemistry.

[41]  Vladimir P Torchilin,et al.  DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Mian Wu,et al.  HIV‐1 TAT‐mediated protein transduction and subcellular localization using novel expression vectors1 , 2002 .

[43]  A. Asokan,et al.  Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. , 2003, Biochimica et biophysica acta.

[44]  C H Wu,et al.  Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. , 1987, The Journal of biological chemistry.

[45]  V. Torchilin,et al.  Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[46]  I. Zuhorn,et al.  On the Mechanism of Cationic Amphiphile-mediated Transfection. To Fuse or not to Fuse: Is that the Question? , 2002, The Journal of Membrane Biology.

[47]  W. Balch,et al.  A new frontier in pharmacology: the endoplasmic reticulum as a regulated export pathway in health and disease , 2001, Expert opinion on therapeutic targets.

[48]  O. Haller,et al.  Antiviral state against influenza virus neutralized by microinjection of antibodies to interferon‐induced Mx proteins. , 1988, The EMBO journal.

[49]  J. Tremblay,et al.  Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins. , 2004, Biochemical and biophysical research communications.

[50]  D. Sheff Endosomes as a route for drug delivery in the real world. , 2004, Advanced drug delivery reviews.

[51]  E. Vivés,et al.  Tat peptide-mediated cellular delivery: back to basics. , 2005, Advanced drug delivery reviews.

[52]  Vladimir P Torchilin,et al.  Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo , 2005, Nature Medicine.

[53]  W. Hong,et al.  Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. , 1998, Seminars in oncology.

[54]  R. Brady,et al.  Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. , 1974, The New England journal of medicine.

[55]  E. Snyder,et al.  Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. , 2001, Current opinion in molecular therapeutics.

[56]  W. Sperl [Diagnosis and therapy of mitochondriopathies]. , 1997, Wiener Klinische Wochenschrift.

[57]  A. Asokan,et al.  Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. , 2002, Journal of pharmaceutical sciences.

[58]  W. Shen,et al.  Quantitative comparison of membrane transduction and endocytosis of oligopeptides. , 2003, Biochemical and biophysical research communications.

[59]  R. Scheule,et al.  Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. , 1997, Human gene therapy.

[60]  A. Harding Neurological disease and mitochondrial genes , 1991, Trends in Neurosciences.

[61]  E. Wider,et al.  Enzyme replacement therapy in porphyrias—II: Entrapment of δ-aminolaevulinate dehydratase in liposomes , 1983 .

[62]  T. Hökfelt,et al.  Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo , 1998, Nature Biotechnology.

[63]  V. Torchilin,et al.  p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. , 2001, Biochimica et biophysica acta.

[64]  S. V. Orlov,et al.  Complexes of Plasmid DNA with Basic Domain 47-57 of the HIV-1 Tat Protein Are Transferred to Mammalian Cells by Endocytosis-mediated Pathways* , 2003, Journal of Biological Chemistry.

[65]  J. Ruysschaert,et al.  Formation and intracellular trafficking of lipoplexes and polyplexes. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  A. Harding,et al.  Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies , 1988, Nature.

[67]  F. Vogel,et al.  Introduction of Plasmid DNA into Isolated Mitochondria by Electroporation , 1997, The Journal of Biological Chemistry.

[68]  Joseph Zabner,et al.  Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid (*) , 1995, The Journal of Biological Chemistry.

[69]  G. Nolan,et al.  Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. , 1997, Journal of immunology.

[70]  J. Kopeček,et al.  Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[71]  V. Torchilin,et al.  Intracellular Targets for DNA Delivery: Nuclei and Mitochondria , 2002, Somatic cell and molecular genetics.

[72]  C. Bonfils,et al.  Cellular localisation of a water-soluble fullerene derivative. , 2002, Biochemical and biophysical research communications.

[73]  I. Summerhayes,et al.  Probing mitochondria in living cells with rhodamine 123. , 1982, Cold Spring Harbor symposia on quantitative biology.

[74]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[75]  Kurt Ballmer-Hofer,et al.  Antennapedia and HIV Transactivator of Transcription (TAT) “Protein Transduction Domains” Promote Endocytosis of High Molecular Weight Cargo upon Binding to Cell Surface Glycosaminoglycans* , 2003, Journal of Biological Chemistry.

[76]  Y. Kagawa,et al.  Gene therapy of mitochondrial diseases using human cytoplasts , 1997, Gene Therapy.

[77]  D. Papahadjopoulos,et al.  pH‐sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules , 1985, FEBS letters.

[78]  D. Rideout,et al.  Mechanism of inhibition of fadu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride , 1994, International journal of cancer.

[79]  D. Escande,et al.  Polyethylenimine but Not Cationic Lipids Promotes Transgene Delivery to the Nucleus in Mammalian Cells* , 1998, The Journal of Biological Chemistry.

[80]  Simon C Watkins,et al.  Efficiency of Protein Transduction Is Cell Type-dependent and Is Enhanced by Dextran Sulfate* , 2002, The Journal of Biological Chemistry.

[81]  M. Pooga,et al.  Cell penetration by transportan. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  Kazunori Kataoka,et al.  Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.

[83]  H. J. Baker,et al.  Enzyme replacement using liposome carriers in feline GM1 gangliosidosis fibroblasts , 1978, Nature.

[84]  Y. Kagawa,et al.  Gene therapy by mitochondrial transfer. , 2001, Advanced drug delivery reviews.

[85]  J. Mai,et al.  Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[86]  Gaetano Villani,et al.  Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases , 1995, Nucleic Acids Res..

[87]  J. Bahn,et al.  Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. , 2001, Free radical biology & medicine.

[88]  R. Brady,et al.  Lectin-specific targeting of beta-glucocerebrosidase to different liver cells via glycosylated liposomes. , 1985, Biochemical medicine.

[89]  T Salditt,et al.  An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. , 1998, Science.

[90]  J. Kuo,et al.  Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[91]  R. Brady,et al.  Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. , 1973, Birth defects original article series.

[92]  D. Piwnica-Worms,et al.  Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. , 2002, Biochemistry.

[93]  G. Gregoriadis Liposomes in the therapy of lysosomal storage diseases , 1978, Nature.

[94]  H. Inokuchi,et al.  Protein Transduction Domain of HIV-1 Tat Protein Promotes Efficient Delivery of DNA into Mammalian Cells* , 2001, The Journal of Biological Chemistry.

[95]  A. Frankel,et al.  Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.

[96]  K. Hruska,et al.  Protein transduction: unrestricted delivery into all cells? , 2000, Trends in cell biology.

[97]  B. E. Ryman,et al.  The use of a liposomally entrapped enzyme in the treatment of an artificial storage condition. , 1976, Biochimica et biophysica acta.

[98]  H. Taubert,et al.  Dequalinium TM Vesicles Form Stable Complexes with Plasmid DNA which Are Protected from DNase Attack , 1999, Biological chemistry.

[99]  T. Fox,et al.  Organelle transformation: shoot first, ask questions later. , 1990, Trends in biochemical sciences.

[100]  A. Weiss,et al.  A disulfide conjugate between anti‐tetanus antibodies and HIV (37–72)Tat neutralizes tetanus toxin inside chromaffin cells , 1999, FEBS letters.

[101]  R. Brady,et al.  Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. , 1973, The New England journal of medicine.

[102]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[103]  S. Carotta,et al.  DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression , 2001, AAPS PharmSci.

[104]  V. Torchilin,et al.  TAT-liposomes: a novel intracellular drug carrier. , 2003, Current protein & peptide science.

[105]  L. Cervenak,et al.  Caveolae--an alternative endocytotic pathway for targeted drug delivery. , 2004, Critical reviews in therapeutic drug carrier systems.

[106]  D. Vestweber,et al.  DNA-protein conjugates can enter mitochondria via the protein import pathway , 1989, Nature.

[107]  A. Ciechanover The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. , 2003, Biochemical Society transactions.

[108]  Y. Eto,et al.  Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodystrophy (twitcher). , 1985, Biochemical and biophysical research communications.

[109]  R. Müller,et al.  Oligomers of the Arginine-rich Motif of the HIV-1 TAT Protein Are Capable of Transferring Plasmid DNA into Cells* 210 , 2003, The Journal of Biological Chemistry.

[110]  G. Gregoriadis,et al.  Enzyme therapy in genetic diseases , 1979, Nature.

[111]  H. Leonhardt,et al.  A novel approach to induce cell cycle reentry in terminally differentiated muscle cells , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[112]  P. Cullis,et al.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids , 2001, Gene Therapy.

[113]  R Weissleder,et al.  High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. , 1999, Bioconjugate chemistry.

[114]  Maurice Green,et al.  Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein , 1988, Cell.

[115]  D. Jo,et al.  Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis , 2005, Nature Medicine.

[116]  R. Desnick,et al.  Enzyme therapy. VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. , 1977, Biochimica et biophysica acta.

[117]  V. Torchilin,et al.  Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy. , 2000, Current pharmaceutical biotechnology.

[118]  D. Escande,et al.  Ca2+‐sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids , 2001, The journal of gene medicine.

[119]  P. Steponkus,et al.  Phase diagram of 1,2-dioleoylphosphatidylethanolamine (DOPE):water system at subzero temperatures and at low water contents. , 1999, Biochimica et biophysica acta.

[120]  A. Prochiantz,et al.  Trojan peptides: the penetratin system for intracellular delivery. , 1998, Trends in cell biology.

[121]  Steven F Dowdy,et al.  Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. , 2005, Advanced drug delivery reviews.

[122]  Kristian Berg,et al.  Photochemical internalisation in drug and gene delivery. , 2004, Advanced drug delivery reviews.

[123]  Kazunori Kataoka,et al.  Block copolymer micelles as long-circulating drug vehicles , 1995 .

[124]  A. Prochiantz,et al.  Antennapedia homeobox peptide regulates neural morphogenesis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[125]  M. Yacoub,et al.  Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport. , 2004, Journal of molecular and cellular cardiology.

[126]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[127]  D. Fischer,et al.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[128]  R. Perez-soler,et al.  Biological characterization of L-asparaginase liposomal formulations , 1996, Cancer Chemotherapy and Pharmacology.

[129]  E. Brambilla,et al.  An electron microscopy study into the mechanism of gene transfer with lipopolyamines. , 1996, Gene therapy.

[130]  J. Fallon,et al.  Specificity of Localization of Myosin‐specific Antibody Fragments in Experimental Myocardial Infarction: Histologic, Histochemical, Autoradiographic and Scintigraphic Studies , 1979, Circulation.

[131]  V. Torchilin,et al.  Targeted delivery of diagnostic agents by surface-modified liposomes , 1994 .

[132]  W. Jiskoot,et al.  OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. , 2004, Biochimica et biophysica acta.

[133]  Lars J. Brandén,et al.  A peptide nucleic acid–nuclear localization signal fusion that mediates nuclear transport of DNA , 1999, Nature Biotechnology.

[134]  H. Wong,et al.  Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain. , 2003, Biochemical and biophysical research communications.

[135]  V. Torchilin Liposomes as targetable drug carriers. , 1985, Critical reviews in therapeutic drug carrier systems.

[136]  J Barsoum,et al.  Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[137]  R. Desnick,et al.  Toward enzyme therapy for lysosomal storage diseases. , 1976, Physiological reviews.

[138]  Vladimir P Torchilin,et al.  Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[139]  J. Coll,et al.  VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[140]  J. Hughes,et al.  Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. , 1999, Bioconjugate chemistry.

[141]  E. Vuorio,et al.  Gene therapy of single-gene disorders: preface to the special section. , 1997, Annals of medicine.

[142]  V. Torchilin,et al.  Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. , 2001, Advanced drug delivery reviews.

[143]  R. Payne,et al.  Targeting proteins to mitochondria using TAT. , 2003, Molecular genetics and metabolism.

[144]  S. Schuster,et al.  Transfer of monoclonal antibodies into mammalian cells by electroporation. , 1989, The Journal of biological chemistry.

[145]  G. Storm,et al.  Liposome-Mediated Targeting of Enzymes to Cancer Cells for Site-Specific Activation of Prodrugs: Comparison with the Corresponding Antibody-Enzyme Conjugate , 2003, Pharmaceutical Research.

[146]  V. Torchilin,et al.  Polymeric micelles for delivery of poorly soluble drugs: Preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids , 2005, Journal of drug targeting.

[147]  N. Phillips,et al.  Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.

[148]  G. Gregoriadis,et al.  Lysosomal localization of -fructofuranosidase-containing liposomes injected into rats. , 1972, The Biochemical journal.

[149]  D. Lasič,et al.  Liposomes: From Physics to Applications , 1993 .

[150]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[151]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[152]  Ph.D. Dr. Sci. Vladimir P. Torchilin Immobilized Enzymes in Medicine , 1991, Progress in Clinical Biochemistry and Medicine.

[153]  M. Belting,et al.  Nuclear Targeting of Macromolecular Polyanions by an HIV-Tat Derived Peptide , 2002, The Journal of Biological Chemistry.

[154]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[155]  J. Lisziewicz,et al.  Antitat gene therapy: a candidate for late-stage AIDS patients. , 1995, Gene therapy.

[156]  G. Elliott,et al.  Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein , 1997, Cell.

[157]  S. Ohta,et al.  Protection against ischemic brain injury by protein therapeutics , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[158]  R. Dwek,et al.  pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. , 2002, Biochemical and biophysical research communications.

[159]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[160]  J. Kopeček,et al.  Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[161]  M. Woodle,et al.  Pharmacokinetics and anti‐tumor activity of vincristine encapsulated in sterically stabilized liposomes , 1995, International journal of cancer.

[162]  G. Gregoriadis,et al.  Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. , 1974, The Biochemical journal.

[163]  G. Kroemer,et al.  Mitochondrion as a novel target of anticancer chemotherapy. , 2000, Journal of the National Cancer Institute.

[164]  J. Rothbard,et al.  Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. , 2005, Advanced drug delivery reviews.

[165]  Vladimir P Torchilin,et al.  Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[166]  Yanli Liu,et al.  Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. , 2004, Bioconjugate chemistry.

[167]  J H Senior,et al.  Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.

[168]  G. Singh,et al.  Mitochondrial contributions to cancer cell physiology: potential for drug development. , 2001, Advanced drug delivery reviews.

[169]  R. Schwendener,et al.  Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes , 2004, Cellular and Molecular Life Sciences CMLS.

[170]  A. Terzic,et al.  Suppression of human tumor cell proliferation through mitochondrial targeting , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[171]  V. Weissig,et al.  DQAsomes: A Novel Potential Drug and Gene Delivery System Made from Dequalinium™ , 1998, Pharmaceutical Research.

[172]  D. Micic,et al.  Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion ‘oxidative stress’ in gerbil brain , 1994, Neurochemical Research.

[173]  D. Anderson,et al.  Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide. , 1993, Biochemical and biophysical research communications.

[174]  J. Fallon,et al.  Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres. , 1982, Science.

[175]  G. Gregoriadis,et al.  TREATMENT OF GAUCHER'S DISEASE WITH LIPOSOME-ENTRAPPED GLUCOCEREBROSIDE: β-GLUCOSIDASE , 1977, The Lancet.